<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区

          Science and Health

          Drugmakers cut vaccine prices for poorer nations

          (Agencies)
          Updated: 2011-06-06 23:07
          Large Medium Small

          LONDON - Several leading drugmakers are cutting their prices on potentially life-saving vaccines for people in developing countries in an effort to sustain supplies via the GAVI international vaccine alliance.

          The price cuts, offered by both generic and branded drugmakers including GlaxoSmithKline, Merck, Johnson & Johnson's Crucell and Sanofi-Aventis' Sanofi Pasteur, should help the alliance narrow a $3.7 billion funding gap for its commitments up until 2015.

          GSK said on Monday it would provide its Rotarix rotavirus vaccine to GAVI at a 67 percent discount to the current public price -- bringing it to $2.50 per dose, or $5 to fully immunise a child.

          Merck said it will offer its Rotateq rotavirus shot at $5.00 a dose initially. "The RotaTeq price will decrease to $3.50 once the purchase volume increases to 30 million doses," it said.

          Julie Gerberding, president of Merck Vaccines said long-term purchase commitments help to speed up availability of vaccines.

          "Confirming volumes to be purchased will enable further price reductions as manufacturers expand production and lower costs in the future allowing for greater access," she added.

          Diarrhoea is one of the top two killers of children under five worldwide and rotavirus is the leading cause of severe diarrhoeal disease in children. Each year, rotavirus-related diarrhoea kills more than 500,000 children.

          In 2009, the WHO recommended that all countries should include rotavirus vaccines in national vaccination programmes, but many poorer countries struggle to afford them.

          GAVI, which funds bulk-buy vaccination programmes for nations that can't afford shots at Western prices, has committed to help fund rotavirus vaccine introduction in at least 40 of the world's poorest countries by 2015.

          But the alliance is facing a shortfall of $3.7 billion to fund it projects through to 2015, and has been seeking extra donor money and price cuts from drug firms to close that gap. It has a pledging conference in London on June 13.

          "These are promising offers that demonstrate industry commitment to work towards affordable and sustainable prices," Helen Evans, GAVI's interim chief executive, said in a statement.

          GSK said it had offered to supply up to 125 million doses of Rotarix over five years at an approximately 95 percent price cut from the Western market price.

          "Whilst most babies in the world will get rotavirus at some point, those in developing countries do not have access to the medical care they need which means millions of babies die unnecessarily," GSK's CEO Andrew Witty said in a statement.

          He said the British drugmaker was committed to finding new ways to get urgently needed vaccines to children in poor countries.

          Evans said that if rotavirus vaccine could be purchased this year at $2.50 a dose, the impact on public health could be significant and would allow GAVI to save approximately $500 million through to 2020, or about $140 million through to 2015.

          The price GAVI pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, will also be cut by the India-based firms Serum Institute and Panacea Biotec.

          Serum, which had already cut its price to $1.75 a dose, said it would "continue to provide the most competitive pricing," while Panacea said it would cut its price by up to 15 percent.

          Crucell and Sanofi Pasteur said they would extend GAVI prices on their pentavalent vaccines to 16 countries who are moving on from GAVI support to begin buying shots themselves.

          Sanofi Pasteur said this would also apply to its yellow fever vaccine and a rotavirus vaccine being developed by its Indian subsidiary Shantha.

          Merck also announced it will offer GAVI its Gardasil shot, which protects the human papillomavirus (HPV) that causes cervical cancer, at a discounted price of $5 per dose -- a 67 percent reduction on the current public price.

          Although GAVI has not yet committed to funding HPV vaccines, it said they were part of its investment strategy and it hoped "to see further price reductions." More than 90 percent of deaths from cervical cancer now occur in developing countries, killing 200,000 women a year.

          分享按鈕
          主站蜘蛛池模板: 综合欧美视频一区二区三区| 日韩精品一区二区三区激情视频 | 久久99久久99精品免视看动漫| 日韩精品人妻中文字幕有码视频| 香蕉EEWW99国产精选免费| 亚洲精品理论电影在线观看| 国产午夜三级一区二区三| 国产精品一亚洲av日韩| 人妻偷拍一区二区三区| 国产欧美日韩免费看AⅤ视频| 午夜男女爽爽影院免费视频下载| 最新国产精品剧情在线ss| 亚洲欧洲日产国无高清码图片| 精品一区二区三区在线成人| 欧美拍拍视频免费大全| 免费无码VA一区二区三区| 久久精品蜜芽亚洲国产av| 欧洲精品码一区二区三区| 韩国理伦片年轻邻居2| 国内精品免费久久久久电影院97| 亚洲人精品午夜射精日韩| 免费人成网站免费看视频| 亚洲区一区二区三区亚洲| 国产精品一二三中文字幕| 精品一卡2卡三卡4卡乱码精品视频| 4hu44四虎www在线影院麻豆| 国产在线无码精品无码| 亚洲人成人网色www| 亚洲精品久久久久久无码色欲四季 | 中文精品无码中文字幕无码专区| 亚洲熟少妇一区二区三区| 国产精品免费重口又黄又粗| 午夜在线观看成人av| 九九日本黄色精品视频| 99热国产这里只有精品9| 日本japanese 30成熟| 欧美人妻在线一区二区| 亚洲一区二区三区高清在线观看| 日本边添边摸边做边爱喷水| 黄色三级视频中文字幕| 久久亚洲综合精品成人网|